GIS's spin-off Auristone secures US$4m in seed funding

2 April 2024 - Congratulations to Auristone, a spin-off from A*STAR’s Genome Institute of Singapore (GIS), on securing US$4M in seed funding to propel the future of precision medicine through epigenomics!

This infusion of capital will strategically enhance Auristone’s capabilities through clinical collaborations, and to drive market adoption of EPI-CALL™, its flagship molecular profiling test that is designed to help doctors and patients navigate the complexities of therapy selection for late-stage cancer patients.